Developments in Pharmacogenomics (Technical Insights)

 


This research service analyzes emerging technologies in the field of pharmacogenomics and their impact on the healthcare industry

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

Developments in Pharmacogenomics (Technical Insights), Executive SummaryIntroductionIntroduction to PharmacogenomicsVariable Drug Response and Adverse ReactionsSNP ProfilingFISHCompanies Involved in Pharmacogenomics ResearchScope and MethodologyScopeMethodologyDevelopments in Pharmacogenomics (Technical Insights), Technology and Applications ViewpointApplications Analysis and TrendsPrimary Applications: Drug Discovery and Molecular DiagnosticsDiagnosis Plus TherapyPersonalized MedicineIndustry Trends and AssessmentsMarket FactorsEnabling Technologies and Their MarketsDevelopments in Pharmacogenomics (Technical Insights), Innovative Developments in North AmericaCompaniesNitroMed: Genetic Variation Determines Response to Heart-Failure DrugGenecor: Second-Generation Interferon-Beta Molecule for Treatment of Multiple SclerosisMonogram Biosciences: Cancer-Specific Dimers Determine Response to ChemotherapyGenizon BioSciences: Small Founder Population Allows Easier Linkage and SNP MappingNanogen: Improved Circuitry Increases Biochip PerformanceAffymetrix: CYP450 Test Approved in USA and EuropeDNAPrint: Fewer SNPs Lower Genotyping CostsSimPheny: Computer Modeling for Predictions of Cellular Metabolism and BehaviorNanosphere: Gold Nanoparticles Allow Molecular Analysis without PCRAdditional Companies-IAdditional Companies-IIAcademic and Government-Related InstitutionsOhio State University: New Molecular Understanding to Tailor Treatments for AddictionMayo Clinic: Protein Misfolding Leads Aggrosome to Disrupt Thiopurine MetabolismUniversity of Florida: Researchers Identify Genes that Influence Response of Heart Failure Patients to Beta-BlockersUniversity of Michigan: Herbal Therapy Potentiates Effect of Blood Thinner by Increasing CYP3A4 ActivityStanford University: Microarrays Predict Drug ResponseNIST: Fluorescent Quantum Dots Reduce FISH UncertaintyUCSF: E-Map Looks at Epistatic InteractionsHarvard University: Automated Microscopy to Track Broad Effects of DrugsDevelopments in Pharmacogenomics (Technical Insights), Innovative Developments in Europe and Asia-PacificCompaniesIceland: deCODE GeneticsUK: SolexaSwitzerland: RocheFrance: Serono Genetics InstituteGermany: Epigenomics Netherlands: Qiagen N.V. India: OcimumIndia: Avestha GengraineIndia: Strand GenomicsAcademic and Government-Related InstitutionsFrance: Magnetic Particles Speed DNA Separations on Chip Germany: Genetic Analysis without Labels Australia: CSIRODevelopments in Pharmacogenomics (Technical Insights), Technology Adoption Factor AnalysisDevelopment Restraints and Market ChallengesIntroductionToo Much Complexity Too Much SimplicityToo Much OptimismClinical Trial Design Understanding Business FundamentalsPracticality of Point-of-CarePharmaceutical Industry ReluctanceGovernmental Support--Financial and IP ProtectionOthersAdoption DriversDrug Side EffectsPressure on Big Pharma to Accelerate Drug Discovery Need for Faster Identification of Failed Targets Identify Suitable Patient Population for Clinical TrialsDemand for Personalized MedicineOthersTechnology Features and BenefitsPart IPart IIAnalysis of Funding SourcesEuropean Government Funding for R&DUSA: Pharmacogenetics Research NetworkCanadian Pharmacogenomic FundingDevelopments in Pharmacogenomics (Technical Insights), Database of Key Industry Participants and Selected PatentsKey Industry ParticipantsNorth AmericaEurope and Asia PacificPatentsPatents--IPatents--IIPatents--IIIDevelopments in Pharmacogenomics (Technical Insights), Frost & Sullivan 2005 Science & Technology AwardsExcellence in Technology AwardAward DescriptionAward RecipientTechnology Innovation AwardAward DescriptionAward RecipientTechnology Leadership AwardAward DescriptionAward RecipientDevelopments in Pharmacogenomics (Technical Insights), Critical Reference TablesHealthcare and Pharma R&D ExpenditureTotal Healthcare Expenditure (1999-2006)Pharma R&D Expenditure (1999-2006)Biotechnology R&D ExpenditureNumber of Biotechnology Companies (1999-2006)Government Investment in Biotechnology R&D (1999-2006)Private Investment in Biotechnology R&D (1999-2006)




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.